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abstract
PURPOSE Preclinical studies demonstrated that ATR inhibition can exploit synthetic lethality (eg, in cancer cells
with impaired compensatory DNA damage responses through ATM loss) as monotherapy and combined with
DNA-damaging drugs such as carboplatin.
PATIENTS AND METHODS This phase I trial assessed the ATR inhibitor M6620 (VX-970) as monotherapy (once or
twice weekly) and combined with carboplatin (carboplatin on day 1 and M6620 on days 2 and 9 in 21-day
cycles). Primary objectives were safety, tolerability, andmaximum tolerated dose; secondary objectives included
pharmacokinetics and antitumor activity; exploratory objectives included pharmacodynamics in timed paired
tumor biopsies.
RESULTS Forty patients were enrolled; 17 received M6620 monotherapy, which was safe and well tolerated. The
recommended phase II dose (RP2D) for once- or twice-weekly administration was 240 mg/m2. A patient with
metastatic colorectal cancer harboring molecular aberrations, including ATM loss and an ARID1A mutation,
achieved RECISTv1.1 complete response and maintained this response, with a progression-free survival of
29 months at last assessment. Twenty-three patients received M6620 with carboplatin, with mechanism-based
hematologic toxicities at higher doses, requiring dose delays and reductions. The RP2D for combination therapy
wasM6620 90mg/m2 with carboplatin AUC5. A patient with advanced germlineBRCA1 ovarian cancer achieved
RECISTv1.1 partial response and Gynecologic Cancer Intergroup CA125 response despite being platinum re-
fractory and PARP inhibitor resistant. An additional 15 patients had RECISTv1.1 stable disease as best response.
Pharmacokinetics were dose proportional and exceeded preclinical efficacious levels. Pharmacodynamic studies
demonstrated substantial inhibition of phosphorylation of CHK1, the downstream ATR substrate.
CONCLUSION To our knowledge, this report is the first of an ATR inhibitor as monotherapy and combined with
carboplatin. M6620 was well tolerated, with target engagement and preliminary antitumor responses observed.
J Clin Oncol 38. © 2020 by American Society of Clinical Oncology
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INTRODUCTION
The DNA damage response (DDR) provides cellular
defense against DNAdamage and is regulated by apical
kinases ATM (ataxia-telangiectasia mutated) and ATR
(ATM and Rad3 related).1 ATM is recruited to double-
strand breaks (DSBs), whereas ATR is recruited to
single-stranded DNA (ssDNA) coated with RPA. ssDNA
can arise from DSB processing or stalled replication
forks (replication stress [RS]). RS can occur when
replication forks encounter unresolved DNA lesions or
the replication rate outpaces the nucleotide supply.2
Both events are common in cancer (eg, from che-
motherapy or oncogenes that drive rapid unscheduled
proliferation).2 Once activated, ATM and ATR signal
DNA damage to cell cycle checkpoints and promote
homologous recombination (HR) repair.3 Despite the
importance of the DDR, many tumors carry ATM
pathway aberrations, placing a reliance on the ATR
pathway for survival.4,5 Preclinical studies demon-
strated that ATR inhibition lethally sensitizes many
tumors with ATM pathway defects to chemotherapy-









at the end of this
article.
Accepted on April 20,
2020 and published at
ascopubs.org/journal/




Downloaded from ascopubs.org by INSTITUTE CANCER RESEARCH on June 30, 2020 from 193.062.218.030
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
asmonotherapy in some cancer cells with ATM loss or other
key DDR aberrations or tumors that express oncogenes,
which drive high RS.6
M6620 (formerly VX-970) is a first-in-class potent ATP-
competitive ATR inhibitor with . 100-fold selectivity
over related kinases (eg, DNA-PK and ATM).7 In pre-
clinical studies, cells defective in ATM signaling were
acutely sensitive to M6620 combined with genotoxic
chemotherapy.7 In mouse xenograft models, M6620
10-20 mg/kg administered intravenously demonstrated
synergistic antitumor efficacy with multiple chemo-
therapeutics, including platinum-based chemotherapy,
often resulting in marked tumor growth inhibition or
regression.7,8 These studies demonstrated that optimal
combination efficacy was achieved when ATR inhibition
was administered after chemotherapy.7
On the basis of these preclinical data, we conducted
a phase I dose-escalation trial to determine safety, tol-
erability, maximum tolerated dose (MTD), pharmacoki-
netics, and antitumor activity of M6620 monotherapy and
combined with carboplatin in patients with advanced
solid tumors. An important objective was to assess the
pharmacodynamic effects of M6620 combined with
carboplatin. Next-generation sequencing (NGS) of ge-
netic aberrations and ATM immunohistochemistry (IHC)
were conducted on archival and/or fresh tumor speci-




Patients age $ 18 years with histologically confirmed ad-
vanced solid tumors refractory to standard therapy and
RECISTv1.1 measurable disease9 were eligible (Data
Supplement).
Study Design
This phase I, open-label trial investigated the safety and
tolerability of M6620 as monotherapy and combined with
carboplatin in patients with refractory solid tumors (Data
Supplement). The study was designed by academic in-
vestigators (T.A.Y. and J.S.d.B.) at the Royal Marsden
Hospital (RMH) and representatives of Vertex Pharma-
ceuticals and conducted at RMH.
Patients received M6620 monotherapy once weekly in
21-day cycles using single-patient dose-escalation cohorts,
expanding to 31 3 cohorts if Common Terminology Criteria
for Adverse Events version 4.010 grade (G) $ 2 toxicities
were observed. The starting dose level (DL) was 60 mg/m2
and was informed by safety results from study VX12-970-
001 (ClinicalTrials.gov identifier: NCT02157792). For the
twice-weekly schedule, M6620 was administered on days 1
and 4, 8 and 11, and 15 and 18 of a 21-day cycle using
a 3 1 3 design, with the starting dose determined by the
highest tolerated dose from the once-weekly schedule.
Pharmacodynamics
Timed tumor biopsies were taken from 12 patients with
accessible disease at predefined time points in cycle 1.
Approximately 22 hours after administration of carboplatin
on day 1, the first biopsy sample was collected. M6620
was administered, and approximately 2 hours later, the
second biopsy was collected (preferably from the same
site). The 2-hour time point was based on preclinical data
that showed that ATR-dependent CHK1 Ser345 phos-
phorylation is lost a few hours after treatment with an ATR
inhibitor.11 After collection, tumor tissues were formalin
fixed and paraffin embedded (FFPE). FFPE blocks were
sectioned and analyzed for pCHK1 staining by IHC using
the rabbit anti–p-Chk1 antibody (Cell Signaling Tech-
nology; Danvers, MA; product number 2348).
CONTEXT
Key Objective
Can ATR inhibition lead to single-agent antitumor activity and enhance the effects of carboplatin chemotherapy safely in
patients with advanced solid tumors, including those with relevant molecular aberrations?
Knowledge Generated
The ATR inhibitor M6620 was well tolerated, with anecdotal single-agent durable RECISTv1.1 complete response in
a patient with metastatic colorectal cancer harboring molecular aberrations, including ATM loss and an ARID1A
mutation. M6620 was well tolerated in combination with carboplatin chemotherapy at biologically active doses, with the
observation of clinical activity in patients with advanced solid tumors, including a patient with platinum-refractory and
PARP inhibitor–resistant germline BRCA1 ovarian cancer.
Relevance
These findings provide early clinical proof of concept that ATR inhibitors may represent a novel antitumor strategy as
monotherapy or in combination with carboplatin chemotherapy in patients with relevant molecular aberrations, including
those who are platinum refractory or PARP inhibitor resistant, which are areas of unmet clinical need.
2 © 2020 by American Society of Clinical Oncology
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RESULTS
Patient Characteristics
Overall, 40 patients were entered into this study and in-
cluded in the safety analysis (Fig 1). All 40 patients received
$ 1 M6620 dose and were considered evaluable for tox-
icity; their characteristics are listed in Table 1. Baseline
mutations and ATM IHC results are reported for assessed
patients in the Data Supplement.
Dose Escalation and Toxicity
M6620 monotherapy. Once-weekly dose escalation pro-
ceeded through DLs of 60 mg/m2 (n5 1), 120 mg/m2 (n5
2), 240 mg/m2 (n5 1), and 480 mg/m2 (n5 7; Fig 1; Data
Supplement), with no dose-limiting toxicities (DLTs) ob-
served. Dose escalation was expanded at 480 mg/m2 once
weekly and capped at this dose, determined to be the
maximal administered dose (MAD), primarily because of
the large infusion volumes required and because this dose
exceeded the human equivalent dose from mouse efficacy
studies (approximately 60 mg/m2). The once-weekly rec-
ommended phase II dose (RP2D) was selected as
240 mg/m2 because of antitumor activity at lower doses
(eg, RECISTv1.1 complete response [CR] at 60 mg/m2)
and prohibitive infusion volumes at 480 mg/m2. A twice-
weekly schedule was assessed in a cohort of 6 patients at
240 mg/m2 (Fig 1; Data Supplement); this dose was well-
tolerated, with no DLTs observed, establishing the twice-
weekly RP2D at 240 mg/m2.
M6620 monotherapy was generally well tolerated for once-
weekly and twice-weekly dosing (Tables 2 and 3). The most
common all-grade, treatment-related, treatment-emergent
adverse events (TEAEs) included flushing (23.5%), nausea
(11.8%), pruritus (11.8%), headache (11.8%), and
infusion-related reactions (11.8%). There were no clinically
relevant trends in electrocardiogram assessments.
Combination M6620 therapy. The starting M6620 dose
combined with carboplatin area under the curve (AUC) 5
was 240mg/m2, 50% of the monotherapy MAD (Fig 1; Data
Supplement). Three patients were treated at DL1, with
DLTs of neutropenia, thrombocytopenia, and lower re-
spiratory tract infection in a heavily pretreated patient with
advanced cholangiocarcinoma. Dose reductions were re-
quired for all 3 patients because of G3/4 treatment-related
neutropenia; although the neutropenia did not constitute
a DLT by protocol, all patients required delays in the start of
cycle 2. The trial safety monitoring committee elected to de-
escalate M6620 to 120 mg/m2, maintaining carboplatin
AUC 5 (DL2). With DL2, 1 patient experienced a DLT of G3
hypersensitivity, and 2 of 3 patients required dose re-
ductions due to G3/4 treatment-related neutropenia and
delays in commencing cycle 2. DL3 explored carboplatin
AUC 4 with M6620 120 mg/m2. At DL3, no DLTs or G3/4
hematologic toxicities were observed, and all 3 patients
received treatment without dose delays, interruptions,
or reductions. DL4 of carboplatin AUC 5 with M6620
90 mg/m2 was explored, and 1 DLT of febrile neutropenia
was observed in a patient with metastatic breast cancer
who recovered without sequelae; she was heavily pre-
treated with 11 lines of cytotoxic therapies. The cohort was
subsequently expanded to include 10 additional patients
(14 total patients), and no other DLTs or G3/4 hematologic
toxicities were observed. The combination therapy RP2D
was established at carboplatin AUC 5 on day 1, with M6620
90 mg/m2 on days 2 and 9 of a 21-day cycle. This is higher
Part A (n = 17)
M6620 monotherapy 
RP2D:
240 mg/m2 once weekly 
Dose level 4 (n = 7)
M6620
480 mg/m2 once weekly
Dose level 3 (n = 1)
M6620
240 mg/m2 once weekly 
Dose level 2 (n = 2)
M6620
120 mg/m2 once weekly 
Dose level 1 (n = 1)
M6620
60 mg/m2 once weekly 
RP2D:
M6620 90 mg/m2 once weekly
+ carboplatin AUC 5 
Part B (n = 23)*
M6620 + carboplatin
Dose level 4 (n = 14)
M6620 90 mg/m2 once weekly
+ carboplatin AUC 5
Dose level 3 (n = 3)
M6620 120 mg/m2 once weekly
+ carboplatin AUC 4
Dose level 2 (n = 3)
M6620 120 mg/m2 once weekly
+ carboplatin AUC 5
Dose level 1 (n = 3)
M6620 240 mg/m2 once weekly
+ carboplatin AUC 5
Twice-weekly RP2D:
240 mg/m2 twice weekly
Dose level 5 (n = 6)
M6620
240 mg/m2 twice weekly
FIG 1. Patient flow di-
agram. AUC, area un-
der the curve; RP2D,
recommended phase II
dose. (*) Part B started
with a dose-escalation
design, but dose re-
ductions were required
because of toxicities.
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than the estimated human dose (body surface area con-
version) equivalent to M6620 10-20 mg/kg administered
intravenously in mouse xenografts, in which efficacy was
observed in combination with cytotoxic chemotherapy,
including platinum agents.8,12
The most common all-grade TEAEs observed with combi-
nation therapy were mechanism-based hematologic toxic-
ities, including neutropenia (47.8% [G3/4, 26.1%]),
thrombocytopenia (39.1% [G3/4, 4.3%]), and anemia
(56.5% [G3/4, 4.3%]). Only 1 nonhematologic G3/4 TEAE
was observed: G3 hypersensitivity reaction at DL2. Other
common all-grade nonhematologic TEAEs included nausea
(52.5%) and fatigue (47.8%). There were no clinically rel-
evant trends in electrocardiogram assessments. All TEAEs
were manageable by standard guidelines and resolved
without sequelae after discontinuation of the drug(s). No
G5 treatment-related TEAEswere observed during the study.
Pharmacokinetic Data
After once-weekly M6620 monotherapy, M6620 expo-
sures increased in a dose-dependent manner in the
60-480 mg/m2 dose range after single (day 1) and multiple
doses (cycle 1, day 8 [C1D8] and C2D1; Table 4). The
mean terminal half-life was 18.5 hours for once-weekly
monotherapy, 12.8 hours for twice-weekly monotherapy,
and 14.3 hours for combination therapy. For twice-weekly
monotherapy, a 6-patient dose cohort was evaluated at
240 mg/m2 with exposures similar to once-weekly dosing,
with no evidence of accumulation. Exposures to M6620
were similar when this was administered asmonotherapy or
combined with carboplatin, indicating no interaction be-
tween M6620 and carboplatin.
Pharmacodynamic Data
To our knowledge, this is the first trial to use precise and
rapidly timed paired biopsy pharmacodynamic data to
confirm target modulation. Of 12 patients who underwent
timed pretreatment and on-treatment tumor biopsies, 5
had both biopsies evaluable (Fig 2). Evaluability was based
on tumor content, tumor fixation, and presence of nuclear
pCHK1 staining. Of the 5 patients, 4 were treated at the
MTD of carboplatin AUC 5 and M6620 90 mg/m2, and
1 received carboplatin AUC 5 and M6620 120 mg/m2.
Overall, a 30%-90% (mean, 67%) reduction in pCHK1
levels was seen in 4 of 5 evaluable biopsy pairs, indicating
ATR inhibition by M6620 and supporting the RP2D se-
lection. Additional analyses will be conducted to validate
these data.
Antitumor Responses
Of 40 patients in the trial, all 17 treated with M6620
monotherapy and 21 of 23 treated with combination
therapy were evaluable for efficacy (2 patients discontinued
TABLE 2. Summary of Treatment-Related TEAEs Reported in . 2 Patients Receiving M6620 Monotherapy
TEAE
M6620 Dose, mg/m2












Grade ‡ 3 All ‡ 3 All ‡ 3 All ‡ 3 All ‡ 3 All ‡ 3 All
Any TEAE 1 (5.9) 15 (88.2) 0 1 (100.0) 0 1 (50.0) 0 0 0 7 (100.0) 1 (16.7) 6 (100.0)
Flushing 0 4 (23.5) 0 0 0 0 0 0 0 3 (42.9) 0 1 (16.7)
NOTE. Data are given as No. (%). AEs are study drug related, which includes “related” and “possibly related” categories. An AE with
relationship missing (unknown) is counted as related.
Abbreviations: AE, adverse event; TEAE, treatment-emergent adverse event.
TABLE 1. Demographic and Clinical Characteristics at Baseline
Characteristic Part A Part B
No. of patients 17 23
Age, years, mean (standard deviation) 63.4 (10.3) 62.0 (8.8)
Sex
Male 7 (41.2) 8 (34.8)
Female 10 (58.8) 15 (65.2)
ECOG PS at baseline
0 4 (23.5) 8 (34.8)
1 13 (76.5) 15 (65.2)
Tumor type
Colorectal cancer 3 (17.6) 8 (34.8)
Mesothelioma 3 (17.6) 2 (8.7)
Ovarian cancer 1 (5.9) 3 (13.0)
Melanoma 1 (5.9) 3 (13.0)
Adenocarcinoma 2 (11.8) 2 (8.7)
Gastric cancer 2 (11.8) 0 (4.3)
Breast cancer 1 (5.9) 1 (4.3)
Cholangiocarcinoma 1 (5.9) 1 (4.3)
Othera 3 (17.6) 3 (8.7)
Median No. of prior therapies (range) 4 (1-10) 3 (2-11)
NOTE. Data given as No. (%) unless otherwise specified.
Abbreviation: ECOG PS, Eastern Cooperative Oncology Group
performance status.
aIn part A, 1 patient each had leiomyosarcoma, gall bladder cancer,
or pancreatic cancer. In part B, 1 patient each had non–small-cell lung
cancer, cervical cancer, or Hurthle cell carcinoma.
4 © 2020 by American Society of Clinical Oncology
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the trial because of infusion reactions and had no efficacy
assessments on treatment; therefore, they did not meet
prespecified inclusion criteria in efficacy analyses). Re-
sponse duration is shown in the Data Supplement. One
patient achieved a RECISTv1.1 CR with M6620 mono-
therapy (Fig 3), and 1 achieved a RECISTv1.1 partial re-
sponse (PR) with combination treatment (Fig 3). Five
patients receiving M6620 monotherapy had a best re-
sponse of RECISTv1.1 stable disease (SD). Fifteen of 21
evaluable patients receiving combination therapy (15 of 23
overall receiving combination therapy) had a best response
of RECISTv1.1 SD, with 10 achieving SD for$ 4 months, of
whom 6 had SD for $ 6 months (Fig 4).
Baseline tumor specimens were available for NGS testing
from 32 patients (1 with pathogenic ATM mutation) and
ATM IHC testing from 30 patients (2 with 100% ATM IHC
loss; Data Supplement). A patient with advanced gall-
bladder cancer had a tumor with an ATM mutation and
100% ATM IHC loss; this patient achieved a best response
of RECISTv1.1 SD but discontinued trial after 11 weeks for
early clinical disease progression. A 55-year-old patient
with KRAS andBRAFwild-type advanced colorectal cancer
had 100% ATM IHC loss in his tumor, but NGS did not
detect an ATMmutation. This patient achieved a RECISTv1.1
PR after 4 cycles of once-weekly 60-mg/m2 M6620 mono-
therapy and a RECISTv1.1 CR after 16 cycles and remained
TABLE 4. Mean (CV%) Pharmacokinetic Parameters of M6620 in Plasma Alone and in Combination With Carboplatin
Time Point Dose (mg/m2) Cmax (ng/mL)
AUC0-‘
(ng ∙ h/mL) Vss (L) CL (L/h) t1/2 (h)
M6620 monotherapy once weekly
Cycle 1, day 1 60 (n 5 1) 286 1,510 888 83.3 8.54
120 (n 5 2) 662 (37) 5,440 (45) 1,080 (43) 49.9 (51) 17.7 (3)
240 (n 5 1) 1,290 6,990 1,090 61.8 13.9
480 (n 5 6) 4,410 (64) 14,900 (34) 1,270 (29) 58.4 (35) 21.2 (18)
M6620 monotherapy twice weekly
Cycle 1, day 1 240 (n 5 6) 1,520 (102) 8,270 (32) 1,040 (32) 51.2 (33) 17.9 (9)
M6620 and carboplatin combination
Cycle 1, day 2 90 (n 5 14) 668 (42) 2,520 (15) 956 (28) 68.5 (22) 12.9 (32)
120 (n 5 6) 607 (39) 3,540 (14) 1,170 (18) 61.4 (16) 16.3 (18)
240 (n 5 3) 2,010 (47) 6,690 (20) 1,180 (34) 68.5 (19) 17.1 (8)
NOTE. Data presented as mean CV (%) unless otherwise indicated.
Abbreviations: AUC0-‘, area under the curve from time zero to infinity; Cmax, maximum concentration; CL, clearance; CV, coefficient of
variation; t1/2, elimination half-life; VSS, volume of distribution at steady state.
TABLE 3. Summary of Treatment-Related TEAEs Reported in . 2 Patients Receiving M6620 Plus Carboplatin Combination Dose
TEAE











Grade ‡ 3 All ‡ 3 All ‡ 3 All ‡ 3 All ‡ 3 All
Any TEAE 7 (30.4) 21 (91.3) 2 (66.7) 3 (100.0) 2 (66.7) 3 (100.0) 0 2 (66.7) 3 (21.4) 13 (92.9)
Anemia 1 (4.3) 13 (56.5) 0 3 (100.0) 0 2 (66.7) 0 1 (33.3) 1 (7.1) 7 (50.0)
Nausea 0 12 (52.5) 0 3 (100.0) 0 2 (66.7) 0 1 (33.3) 0 6 (42.9)
Neutropenia 5 (21.7) 11 (47.8) 2 (66.7) 3 (100.0) 1 (33.3) 2 (66.7) 0 0 2 (14.3) 6 (42.9)
Thrombocytopenia 1 (4.3) 9 (39.1) 1 (33.3) 3 (100.0) 0 1 (33.3) 0 1 (33.3) 0 4 (28.6)
Fatigue 0 9 (39.1) 0 2 (66.7) 0 1 (33.3) 0 0 0 6 (42.9)
Peripheral neuropathy 0 4 (17.4) 0 2 (66.7) 0 0 0 0 0 2 (14.3)
Infusion-related reaction 0 4 (17.4) 0 1 (33.3) 0 1 (33.3) 0 0 0 2 (14.3)
Flushing 0 4 (17.4) 0 1 (33.3) 0 0 0 1 (33.3) 0 2 (14.3)
Pruritus 0 3 (13.0) 0 1 (33.3) 0 0 0 1 (33.3) 0 1 (7.1)
Hypomagnesemia 0 3 (13.0) 0 0 0 0 0 0 0 3 (21.4)
NOTE. Data are given as No. (%). AEs are study drug related, which includes “related” and “possibly related” categories. An AE with
relationship missing (unknown) is counted as related.
Abbreviations: AE, adverse event; AUC, area under the curve; TEAE, treatment-emergent adverse event.
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FIG 2. Pharmacodynamic profile of M6620. (A) Ataxia telangiectasia and Rad3-related protein (ATR) pathway schematic. (B) Biopsy schematic.
(C) Patient characteristics for biopsy study. (D) Spaghetti plot. (E) Phosphorylated checkpoint kinase 1 (pCHK1) immunohistochemistry (IHC) image
from patient 23; predose biopsy (top) and postdose biopsy (bottom), with negative immunoglobulin G (IgG) controls on the right. Approx, ap-
proximately; AUC, area under the curve.
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in RECISTv1.1 CR with an ongoing progression-free survival
(PFS) of 29 months at last assessment (Fig 3). This re-
sponder had previously experienced disease progression on
multiple lines of chemotherapy, including folinic acid and
5-fluorouracil combined with oxaliplatin, folinic acid and
5-fluorouracil combined with irinotecan, bevacizumab,
cetuximab, capecitabine and mitomycin C, and radiother-
apy. Mismatch repair deficiency was confirmed by IHC, with
loss of MLH1 and PMS2 protein expression. No germline
mismatch repair gene alterations were identified. Whole-
exome NGS confirmed mismatch repair deficiency with
a truncating somatic mutation inMLH1 and a complex array
of other nonsynonymous truncatingmutations in DNA repair
enzymes, including two heterozygous truncating mutations
in ARID1A and heterozygous truncating mutations in
CHEK1, FANCM, RAD50, POLD1, and FANCP (SLX4)
(Data Supplement). Loss of ARID1A protein expression was
confirmed by IHC, suggesting that the two ARID1A mu-
tations may be in trans, or that mutation of one allele is
sufficient for loss at the protein level as observed in other
tumor types.13 The patient had detectable levels of ARID1A,
CHEK1, FANCM, RAD50, PTEN, MLH1, and MSH6 mu-
tations in circulating free DNA at baseline. The allele fre-
quencies of these mutations declined with M6620 therapy,
with ARID1A and FANCM mutation rates decreasing to
undetectable levels in circulating free DNA by C5D1 and
MLH1 mutations becoming undetectable by C9D1.
In the M6620-carboplatin combination cohort, a confirmed
RECISTv1.1 PR was observed in a 54-year-old woman with
heavily pretreated metastatic high-grade serous ovarian
cancer, who was treated at the combination RP2D. Bio-
marker analyses confirmed germline BRCA1 Q1111Nfs*5
C
Baseline
































FIG 3. Patient with colorectal cancer who achieved a RECISTv1.1 complete response (CR) to M6620monotherapy. (A, B) At last assessment, the patient
remained in RECISTv1.1 CR with an ongoing progression-free survival of 29 months. At trial baseline, the patient had disease progression in his left
common iliac lymph nodes, the largest of which measured 30 mm along the long axis and 18 mm along the short axis (B, top panel). There was also
disease progression with worsening peritoneal disease in his anterior abdomen and asymmetric thickening of his transverse colon lateral to surgical clips,
in keeping with a local tumor recurrence with transmural infiltration (B, bottom panel). (A) Immunohistochemistry of archived tumor sample showed
ataxia-telangiectasia mutated (ATM) loss (left) and AT-rich interaction domain 1A (ARID1A) loss (right). Patient also had other relevant aberrations (see
Results section). (B) Computed tomography scans before treatment (left) and 29 months after treatment (right) demonstrated response of left common
iliac lymph node and other lesions to single-agent M6620. Top panel shows left common iliac node. Bottom panel shows local recurrence in transverse
colon with peritoneal malignant infiltration and left para-aortic nodes. (C, D) Patient with ovarian cancer achieved a RECISTv1.1 partial response to
M6620 plus carboplatin combination therapy. (C) Computed tomography scans before (left) and 5months after therapy (right) showed partial response of
left peritoneal disease. (D) There was a corresponding decrease in cancer antigen 125 (CA125) levels, which was a Gynecologic Cancer Intergroup
response.
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mutation and TP53 Y220C missense deleterious somatic
mutation (Data Supplement). Her oncology history in-
cluded initial debulking surgery before 7 lines of different
chemotherapy regimens and molecularly targeted agents,
including multiple rechallenges with platinum-based che-
motherapy before developing platinum-refractory disease
on carboplatin-gemcitabine chemotherapy. This patient
also received 2 prior lines of PARP inhibitor therapies,
achieving a RECISTv1.1 PR lasting 10months with the first,
before developing disease progression. She then received
a different PARP inhibitor in combination with an AKT
inhibitor, achieving RECISTv1.1 SD with minor tumor re-
gression lasting 5 months, before developing disease
progression. She achieved a confirmed RECISTv1.1 PR
and Gynecologic Cancer Intergroup CA125 response
lasting 6 months with M6620-carboplatin combination
therapy at the RP2D (Fig 3). Pharmacodynamic analysis of
this patient confirmed on-target ATR inhibition with
73% reduction in pCHK1 expression (Fig 2).
DISCUSSION
To our knowledge, this report is the first of an ATR inhibitor
as monotherapy and combined with carboplatin. The ra-
tionale for the trial comes from extensive preclinical studies
demonstrating that ATR inhibition lethally sensitizes many
cancer cells to DNA-damaging chemotherapies, including
carboplatin, and that ATR inhibition can be effective as
monotherapy in cancer cells with aberrations that impair
alternative repair pathways or that induce high RS.5-7
M6620 was initially assessed in this trial as monotherapy on
once- and twice-weekly schedules. The drug was well
tolerated, with no DLTs on either schedule. The RP2D was
established at 240 mg/m2 both once and twice weekly.
Pharmacokinetics on both schedules were dose pro-
portional, and the observed half-life of M6620 was 12.8-
18.5 hours. Although this trial enrolled a heavily pretreated,
“all-comer” patient population, 1 patient with advanced co-
lorectal cancer, treated with once-weekly M6620 60 mg/m2,
achieved a durable RECISTv1.1 CR that was ongoing, with
a PFS of 29months at last assessment. NGS and IHC analyses
of the tumor revealed multiple defects in DDR genes and
proteins, specifically, heterozygous truncating mutations in
CHK1, FANCM, RAD50, POLD1, and FANCP; compound
heterozygous truncating mutations in ARID1A; and loss of
ATM and ARID1A protein by IHC. Interestingly, many of these
genes have been associated with DDR, and, specifically, ATR
signaling (FANCM, CHK1, ATM), or have a synthetic lethal
relationship with ATR inhibition in vitro and/or in vivo (POLD1,
ATM, ARID1A).6,14-19 After M6620 treatment, the allele fre-
quency of ARID1A and FANCM mutations became un-
detectable, consistent with cells carrying these mutations
being sensitive to treatment. These observations and muta-
tions in DDR genes suggest that this exceptional responder
had substantial disruption of DNA repair processes, placing an
acute reliance on ATR for tumor cell survival.
In combination therapy, M6620 was administered 24 hours
after carboplatin administration. This was based on pre-
clinical studies, which demonstrated that maximum effi-
cacy was achieved with administration of ATR inhibitor 12-
24 hours after DNA-damaging chemotherapy, coincident
with peak accumulation of cells in S-phase and concom-
itant ATR activation.8 Although DLTs within cycle 1 were not
observed, mechanism-based myelosuppression resulted in
dose delays in carboplatin retreatment in several patients,
leading to the RP2D of M6620 90 mg/m2 with carboplatin
AUC 5. A reduced RP2D for M6620 in combination with
carboplatin versus monotherapy is consistent with exten-
sive preclinical studies that demonstrated that nontumor
cells undergo transient growth arrest in response to ATR
inhibition and DNA damage and that sensitivity to ATR
inhibition increases with DNA damage.6-8 Importantly,











































































FIG 4. Maximum change
from baseline in the sum
of target tumor lesion di-
ameters with combina-
tion therapy. AUC, area
under the curve; PD,
progressive disease; PR,
partial response; SD, sta-
ble disease.
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demonstrated in the clinic at the RP2D, consistent with the
pharmacokinetics and preclinical studies that demonstrated
that short periods of transient ATR inhibition (, 2 hours) are
sufficient to achieve marked synergy with cytotoxic che-
motherapy.11 Pharmacokinetic studies confirmed that
M6620 exposures were dose dependent, with no evidence
of accumulation or interaction with carboplatin.
To gain evidence for ATR activation by carboplatin at the
point of M6620 administration (24 hours after carboplatin
administration) and to test target engagement at the RP2D,
pharmacodynamic studies were undertaken to assess the
impact of treatment on CHK1 phosphorylation. Numerous
studies have demonstrated that tumor is the optimal tissue
to assess pharmacodynamic effects relative to surrogate
tissue.20,21 We therefore performed a carefully timed paired
tumor biopsy study in which patients first underwent biopsy
24 hours after carboplatin chemotherapy, immediately
before M6620 administration. This served to assess ATR
activation in response to carboplatin (informing if a 24-hour
dose delay was appropriate) and as a baseline for the post-
M6620 biopsy. This second biopsy was taken within
2 hours of M6620 administration. This tight window is
critical, because preclinical studies showed that cells at-
tempt to compensate for ATR inhibition by activating other
repair kinases that act on Ser345 of CHK1 (by 2-4 hours).11
Five patients had appropriate tumor tissue in their paired
biopsy samples. Four patients showed substantial de-
pletion of pCHK1 while receiving treatment with M6620,
indicating that the carboplatin combination RP2D/MTD of
M6620 90 mg/m2 effectively inhibited ATR.
Despite being a heavily pretreated population\ that was
refractory to standard-of-care therapeutic options, 15 of
21 patients eligible for efficacy assessment (15 of 23 overall
patients) in the combination arm showed a best response of
RECISTv1.1 SD, and 1 treated at the RP2D achieved
a RECISTv1.1 PR lasting 6 months. This response was
notable because the patient, with advanced high-grade
serous ovarian cancer, had disease progression on prior
PARP inhibitor therapy twice and was platinum refractory.
The patient had a germline BRCA1mutation that remained
evident on NGS of the pretreatment tumor biopsy and
a TP53 (Y220C) missense mutation. Her persistent BRCA1
mutation with platinum-refractory and PARP inhibitor–
resistant disease (despite initially responding to PARP in-
hibition), which was responsive to retreatment with plati-
num in combination with ATR inhibition, is an intriguing
finding. It is consistent with the hypothesis that in response
to PARP inhibitor therapy or platinum chemotherapy, the
tumor acquired a mechanism to activate HR despite
retaining BRCA1 deficiency, which can then be blocked
with ATR inhibition. It highlights a potential opportunity for
ATR inhibitors in restoring platinum sensitivity and treating
patients with relapsed BRCA1/2 mutant disease. A recent
study also showed that the combination of M6620 and
topotecan was generally well tolerated and demonstrated
preliminary antitumor activity in platinum-refractory small-
cell lung cancer22; a recent phase II study also reported
longer PFS with M6620 combined with gemcitabine versus
gemcitabine alone in patients with platinum-resistant high-
grade serous ovarian cancer.23
In summary, M6620 is well-tolerated as monotherapy and
in combination with carboplatin. A timed paired tumor
biopsy study with the M6620-carboplatin combination
supports preclinical data indicating that delayed adminis-
tration of M6620 is appropriate and that the RP2D is
sufficient to inhibit ATR activity in tumors. Two patients
achieved RECISTv1.1 responses, 1 with M6620 mono-
therapy and the other in combination with carboplatin.
Multiple trials are ongoing with M6620 and other ATR
inhibitors as monotherapy and in rational combinations,
such as with DNA-damaging agents.24
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